Get started
Author

Shih‐Feng Cho

Observed names: S.F. Cho, S.‐F. Cho, Shih Feng Cho, Shih-Feng Cho
ORCID: 0000-0002-9884-9429
Observed ORCID: 0000-0002-9884-9429
OpenAlex ID: A5031772152
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
2018 · Shih-Feng Cho, Kenneth C. Anderson, et al. · Frontiers in Immunology · 294
PDF
MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression
2014 · Shih-Feng Cho, Yuli Christine Chang, et al. · BMC Cancer · 155
PDF
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
2019 · Hui-Ching Wang, Leong-Perng Chan, et al. · Frontiers in Oncology · 99
PDF
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
2020 · Liang Lin, Shih-Feng Cho, et al. · Leukemia · 89
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
2018 · Yu-Tzu Tai, Liang Lin, et al. · Leukemia · 89
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
2020 · Shih-Feng Cho, Liang Lin, et al. · Blood Advances · 74
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
2018 · Yu-Tzu Tai, Shih-Feng Cho, et al. · Frontiers in Immunology · 67
PDF
Bispecific antibodies in multiple myeloma treatment: A journey in progress
2022 · Shih-Feng Cho, Tsung-Jang Yeh, et al. · Frontiers in Oncology · 60
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
2020 · Lijie Xing, Liang Lin, et al. · Leukemia · 60
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
2022 · Hailin Chen, Tengteng Yu, et al. · Blood Cancer Journal · 57
PDF
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
2020 · Shih-Feng Cho, Liang Lin, et al. · Cancers · 54
PDF
Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy
2017 · Chin-Chuan Chang, Shih-Feng Cho, et al. · Oncotarget · 52
PDF
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
2020 · Tengteng Yu, Bharat Chaganty, et al. · Blood Cancer Journal · 43
PDF
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
2021 · Shih-Feng Cho, Lijie Xing, et al. · Cancers · 40
PDF
COVID-19 Pandemic Is Associated with an Adverse Impact on Burnout and Mood Disorder in Healthcare Professionals
2021 · Yu-Yin Lin, Yu-An Pan, et al. · International Journal of Environmental Research and Public Health · 36
PDF
Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
2018 · Yu-Fen Tsai, Wen-Chuan Huang, et al. · Medicine · 31
Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
2021 · Hui‐Jen Tsai, Hui‐Hua Hsiao, et al. · Cancer Medicine · 29
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
2021 · Lijie Xing, Su Wang, et al. · Clinical Cancer Research · 28
AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
2019 · Shih-Feng Cho, Liang Lin, et al. · Blood · 28
Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment
2018 · Shih-Feng Cho, Liang Lin, et al. · Blood · 27
SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma
2012 · Chin-Chuan Chang, Shih-Feng Cho, et al. · Clinical Nuclear Medicine · 26
Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
2019 · Yu-Fen Tsai, Ching-I Yang, et al. · PeerJ · 24
Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study
2015 · Shih-Feng Cho, Wan-Hsuan Wu, et al. · Scientific Reports · 23
PDF
Higherlipocalin 2expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia
2012 · Wen-Chi Yang, Pai-Mei Lin, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Previous Exposure to Statin May Reduce the Risk of Subsequent Non-Hodgkin Lymphoma: A Nationwide Population-Based Case-Control Study
2015 · Shih-Feng Cho, Yi-Hsin Yang, et al. · PLoS ONE · 20
PDF
Works count: 112
Citation count: 1,931
H-index: 23
I10-index: 43
Year
Topic
Type